BRANFORD, Conn. --(BUSINESS WIRE)--Jul. 25, 2024-- Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage
BRANFORD, Conn. --(BUSINESS WIRE)--Jul. 23, 2024-- Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of a public offering of an aggregate of 6,665,000 shares of
Newly issued U.S. patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis. Issuance date was July 16, 2024 Newly allowed patents in the U.S. and China protect the composition of a filaggrin-secreting strain of Staphylococcus epidermidis
Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024 BRANFORD, Conn. --(BUSINESS WIRE)--Jun. 27, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it
BRANFORD, Conn. --(BUSINESS WIRE)--May 31, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held
ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in
ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome Topical application of ATR-12 to ex vivo human skin results in superior LEKTI delivery compared to topical LEKTI application ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome Safe
BRANFORD, Conn. --(BUSINESS WIRE)--May 9, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024 , and provided a business
Azitra will present two oral presentations at ASGCT ( American Society of Gene and Cell Therapy ) Baltimore, MD , May 7-11, 2024 related to ATR-12, Azitra’s candidate for Netherton syndrome Topical application of ATR-12 to ex vivo human skin demonstrates the potential for superior LEKTI delivery
ASGCT ( American Society of Gene and Cell Therapy ) Baltimore, MD , May 7-11, 2024 SID ( Society of Investigative Dermatology ) Dallas, TX , May 15-18, 2024 ASCO ( American Society of Clinical Oncology ) Chicago, IL , May 31 – June 4, 2024 BRANFORD, Conn. --(BUSINESS WIRE)--Apr.